BioArctic AB (publ) (BRCTF PINK) stock market data APIs
$31.8667
0(0%)
as of October 16, 2025
Try our APIs with
free plan!
BioArctic AB (publ) Financial Data Overview
Price chart is built with
Anychart
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Prev. Close
31.8667
Open
31.8667
High
31.8667
Low
31.8667
52 wk Range
12.9435-36.83
Market Cap
2 858 M
P/E Ratio
25.5238
Shares Outstanding
74 237 K
Revenue
1 860 M
EPS
0.1129
Beta
-0.727
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioArctic AB (publ) data using free add-ons & libraries
Get BioArctic AB (publ) Fundamental Data
BioArctic AB (publ) Fundamental data includes:
- Net Revenue: 1 860 M
- EBITDA: 1 301 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-28
- EPS/Forecast: 1.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioArctic AB (publ) News
New
Will Eisai’s (TSE:4523) At-Home Alzheimer’s Injection Redefine Its Competitive Edge in Neuroscience?
Earlier this month, BioArctic AB announced that Leqembi Iqlik, the subcutaneous autoinjector formulation of lecanemab, became available in the U.S. as a maintenance dosing option for early Alzheimer's...
First patient treated with Leqembi® (lecanemab) in the Nordics
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and that the first patie...
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generi...
Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for maintenance dosing in ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
